{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-210295","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.876575+00:00","generated_at":"2026-05-14T21:56:35.756549+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29","bullets":["R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.","Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.","Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.","Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.","CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-210295","json":"https://secwatch.observer/filing/0001193125-26-210295.json","markdown":"https://secwatch.observer/filing/0001193125-26-210295.md","text":"https://secwatch.observer/filing/0001193125-26-210295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/0001193125-26-210295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/clym-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:56:35.756549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1900786cda1f78bf7e07620a577bbbb8140cfbe6","claim":"Climb Bio, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 7, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/0001193125-26-210295-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}